Sera Prognostics, Inc.
corporate_fare Company Profile
Sera Prognostics, Inc. (NASDAQ:SERA) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 14 items for SERA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for SERA spans 10-Q, 8-K, 424B5, 10-K.
Recent high-impact activity:
- Sera Q3 10-Q: $42K Revenue, $72.8M Cash, $25.6M Nine-Month Net Loss
- PreTRM Volume Jumps 54% Sequentially as Florida Medicaid Adds Coverage
- Sera Prognostics Q2 Revenue Rises on Medicaid Mandate and New Partnerships
- Sera Prognostics Q2 2026: Revenue Climbs 76% YoY, Cash Runway Extended to 2029
- Sera Prognostics Appoints Former Myriad Genetics CEO Mark Capone to Board
Financial Snapshot
Short Interest & Short Volume
9.12 days to coverFINRA reported short interest of 219,751 shares in SERA as of the October 30, 2026 settlement, a 1.3% decrease from the prior period — about 9.1 days to cover at its recent average daily volume. On November 20, 2026, 26.2% of SERA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.